The use of medicinal cannabis as an alternative treatment for depressive disorders: integrative review
O uso de canabis medicinal como tratamento alternativo para transtornos depressivos: revisão integrativa
Palavras-chave:
Depression, Medical cannabis, Cannabidiol, CannabinoidsResumo
Objective: to analyze, through an integrative review, the use and applicability of medicinal cannabis as a complementary treatment in patients with depression such as unipolar disorder. Methods: the research question was “Is it effective in using medicinal cannabis as a complementary method for treating patients with depression due to unipolar disorder?”. The databases used were PubMed and Portal Capes (published between 2018-2023), with the search strategy (Depression” OR “Psychic Symptoms”) AND (“Cannabidiol” OR “Cannabis”) AND (“Young Adult” OR “Adolescent” OR “Young”). Results: there is work that supports the use of cannabis as an alternative treatment for depression; the majority, however, affirm the ineffectiveness of the compound in improving depression, with some even demonstrating its harm. Positive results ranged from 34.8% to 53% of the sample. Conclusion: there is no rigorous consensus on the benefits and harms of the medicine, and new research in the area is necessary.
Downloads
Referências
BAHORIK, A. L. et al. Medical and non-medical marijuana use in depression: Longitudinal associations with suicidal ideation, everyday functioning, and psychiatry service utilization. Journal of Affective Disorders, v. 241, p. 8–14, 1 dez. 2018.
BARROS, M. B. DE A. et al. Report on sadness/depression, nervousness/anxiety and sleep problems in the Brazilian adult population during the COVID-19 pandemic. Epidemiologia e Servicos de Saude, v. 29, n. 4, 2020.
CAMPOS, F. A. A. C.; FEITOSA, F. B. Creating a Protocol for Diagnosis of Depression. Enfermería: Cuidados Humanizados, v. 6, n. 2, 27 out. 2017.
DENNEN, C. A. et al. Neurogenetic and Epigenetic Aspects of Cannabinoids. EpigenomesMDPI, , 1 set. 2022. Disponível em: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498086/>. Acesso em: 22 ago. 2023
HASBI, A.; MADRAS, B. K.; GEORGE, S. R. Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review. Brain SciencesMDPI, , 1 fev. 2023.
KAPCZINSKI, F.; QUEVEDO, J.; IZQUIERDO, I. Bases Biológicas dos Transtornos Psiquiátricos. 3. ed. Porto Alegre: Artmed, 2011.
LEUNG, J. et al. Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada. Psychopharmacology, v. 239, n. 5, p. 1509–1519, 12 maio 2022.
MARTIN, E. L. et al. Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial. Frontiers in Psychiatry, v. 12, 9 set. 2021.
MEDEIROS, D. DE C. et al. The Endocannabinoid System Activation as a Neural Network Desynchronizing Mediator for Seizure Suppression. Frontiers in Behavioral NeuroscienceFrontiers Media S.A., , 13 nov. 2020. Disponível em: <https://pubmed.ncbi.nlm.nih.gov/33281577/>. Acesso em: 8 nov. 2023
PARRELLA, N. F. et al. A systematic review of cannabidiol trials in neurodevelopmental disorders. Pharmacology Biochemistry and BehaviorElsevier Inc., , 1 set. 2023.
PEREIRA, M. T. C. G.; SOUZA, F. A. M. DE; CARDOSO, F. M. Tratamento medicamentoso para depressão e prevenção quaternária. Revista Brasileira de Medicina de Família e Comunidade, v. 16, n. 43, p. 2568, 26 set. 2021.
PERON, A. P. et al. Aspectos Biológicos e Sociais da Depressão. Ciênc. Saúde Unipar, v. 8, n. 1, p. 45–48, 2004.
RAPIN, L. et al. Cannabidiol use and effectiveness: real-world evidence from a Canadian medical cannabis clinic. Journal of Cannabis Research, v. 3, n. 1, 1 dez. 2021.
SILVA, R. R. DA; ALMEIDA, D. G. DE; SANTOS, J. S. A utilização da Cannabis sativa para o tratamento da depressão. Research, Society and Development, v. 11, n. 14, p. e58111435786, 19 out. 2022.
STACK, S. K. et al. The Effectiveness and Adverse Events of Cannabidiol and Tetrahydrocannabinol Used in the Treatment of Anxiety Disorders in a PTSD Subpopulation: An Interim Analysis of an Observational Study. Journal of Pharmacy Technology, v. 39, n. 4, p. 172–182, 1 ago. 2023.
STANCIU, C. N. et al. Evidence for use of cannabinoids in mood disorders, anxiety disorders, and ptsd: A systematic review. Psychiatric ServicesAmerican Psychiatric Association, , 1 abr. 2021. Disponível em: <https://pubmed.ncbi.nlm.nih.gov/33530732/>. Acesso em: 19 ago. 2023
TAIT, M. A. et al. Health-related quality of life in patients accessing medicinal cannabis in Australia: The QUEST initiative results of a 3-month follow-up observational study. PLoS ONE, v. 18, n. 9 September, 1 set. 2023.
TENG, C. et al. Epidemiologia e ônus da depressão resistente ao tratamento no Brasil: análise do subgrupo brasileiro do estudo de observação multicêntrico TRAL. Jornal Brasileiro de Economia da Saúde, v. 13, n. 3, p. 310–321, dez. 2021.
WIECKIEWICZ, G. et al. Cannabidiol (CBD) in the Self-Treatment of Depression-Exploratory Study and a New Phenomenon of Concern for Psychiatrists. Frontiers in Psychiatry, v. 13, 22 mar. 2022.
